Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0DL7P
|
|||
| Drug Name |
Diazepinone derivative 4
|
|||
| Synonyms |
PMID28067079-Compound-87
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-10: G20] | Patented | [1], [2], [3] | |
| Reflux disease [ICD-11: DA22] | Patented | [1] | ||
| Company |
NOVARTIS AG BEHNKE, Dirk CARCACHE, David ERTL, Peter KOLLER, Manuel ORAIN, David
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H19FN4O2
|
|||
| Canonical SMILES |
COC1=NC=CC(=C1)C2=NCC(=O)N3CCC4=C(C=CC=C4C3=C2)C5=CN=C(C=C5)F
|
|||
| InChI |
1S/C24H19FN4O2/c1-31-23-11-15(7-9-26-23)20-12-21-19-4-2-3-17(16-5-6-22(25)28-13-16)18(19)8-10-29(21)24(30)14-27-20/h2-7,9,11-13H,8,10,14H2,1H3
|
|||
| InChIKey |
GISRGWUSGUAUMX-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Metabotropic glutamate receptor 5 (mGluR5) | Target Info | Modulator | [1] |
| Target's Patent Info | Metabotropic glutamate receptor 5 (mGluR5) | Target's Patent Info | [1] | |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Long-term potentiation | ||||
| Retrograde endocannabinoid signaling | ||||
| Glutamatergic synapse | ||||
| Huntington's disease | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||
| Metabotropic glutamate receptor group III pathway | ||||
| Metabotropic glutamate receptor group I pathway | ||||
| Endogenous cannabinoid signaling | ||||
| Reactome | G alpha (q) signalling events | |||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| WikiPathways | Hypothetical Network for Drug Addiction | |||
| GPCRs, Class C Metabotropic glutamate, pheromone | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. | |||
| REF 2 | Caspase inhibitors: a review of recently patented compounds (2013-2015).Expert Opin Ther Pat. 2018 Jan;28(1):47-59. | |||
| REF 3 | 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.